Literature DB >> 31949847

Long non-coding RNA Ftx promotes osteosarcoma progression via the epithelial to mesenchymal transition mechanism and is associated with poor prognosis in patients with osteosarcoma.

Bo Li1, Peng Ren2, Zhiyong Wang3.   

Abstract

OBJECTIVE: Long non-coding RNA Ftx (lncRNA Ftx) is involved in a variety of cancers. However, the association between lncRNA Ftx and osteosarcoma is still unclear. In this study, we investigated the correlation between lncRNA Ftx and osteosarcoma, and the regulative effect of Ftx on the migration and invasion of osteosarcoma cells, as well as its molecular mechanism.
METHODS: Expression levels of lncRNA Ftx in osteosarcoma tissues and adjacent non-tumor corresponding tissues (ANCTs) were detected using quantitative real-time PCR (qRT-PCR). Differences in patient survival were determined by the Kaplan-Meier method and a log-rank test. The Cox regression analysis was used for univariate and multivariate analyses of prognostic values. Human osteosarcoma cell lines Saos2 and HOS were transfected with the pcDNA-Ftx constructs. The scratch wound healing assay and Transwell assay were used to assess cell migration and invasion capability, respectively. Western blot analysis was conducted to investigate the expression of mesenchymal and epithelial markers.
RESULTS: The results showed that the lncRNA Ftx group was higher in osteosarcoma tissues compared with the ANCTs group. Expression of lncRNA Ftx was correlated with the clinical stage and distant metastasis (P<0.05). The overall survival rate was lower in the high lncRNA Ftx group than in the low lncRNA Ftx group (log-rank test, P<0.05). Multivariate analysis revealed that in osteosarcoma patients, higher lncRNA MEG3, advanced clinical stage, and distant metastasis were all independent predictors of overall survival. Cell research showed that transfection of lncRNA Ftx significantly promoted the migration and invasion ability of osteosarcoma cells. In addition, E-cadherin was decreased, while N-cadherin and Snail-1 were increased, at both the protein and mRNA levels. Pre-treatment with Snail-1 siRNA abrogated the promotion effect of Ftx on the migration and invasion of osteosarcoma cells.
CONCLUSIONS: Increased expression of lncRNA Ftx could not only be a biomarker for progression and prognosis of osteosarcoma, but also could regulate the development of osteosarcoma via the epithelial to mesenchymal transition (EMT) mechanism. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Snail-1; epithelial to mesenchymal transition; lncRNA Ftx; osteosarcoma

Year:  2018        PMID: 31949847      PMCID: PMC6962994     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

Review 1.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

2.  Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.

Authors:  Gong Cheng; Changying Liu; Xiujiang Sun; Lei Zhang; Lifang Liu; Jun Ouyang; Bo Li
Journal:  Oncol Rep       Date:  2015-06-11       Impact factor: 3.906

3.  Biological significance of long non-coding RNA FTX expression in human colorectal cancer.

Authors:  Xiao-Bo Guo; Zhu Hua; Chen Li; Li-Pan Peng; Jing-Shen Wang; Bo Wang; Qiao-Ming Zhi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database.

Authors:  Benjamin J Miller; Peter Cram; Charles F Lynch; Joseph A Buckwalter
Journal:  J Bone Joint Surg Am       Date:  2013-07-03       Impact factor: 5.284

Review 5.  The emergence of lncRNAs in cancer biology.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-10       Impact factor: 39.397

6.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

7.  Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.

Authors:  Yang Jin; Zilian Cui; Xudong Li; Xunbo Jin; Jian Peng
Journal:  Oncotarget       Date:  2017-04-18

8.  Knockdown of Long Noncoding RNA FTX Inhibits Proliferation, Migration, and Invasion in Renal Cell Carcinoma Cells.

Authors:  Xiangfei He; Fuguang Sun; Fengfu Guo; Kai Wang; Yisheng Gao; Yanfei Feng; Bin Song; Wenzhi Li; Yang Li
Journal:  Oncol Res       Date:  2016-10-26       Impact factor: 5.574

9.  Role of Long Noncoding RNA HOTAIR in the Growth and Apoptosis of Osteosarcoma Cell MG-63.

Authors:  Hua Zheng; Jing Min
Journal:  Biomed Res Int       Date:  2016-08-31       Impact factor: 3.411

10.  Visfatin Destabilizes Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice.

Authors:  Bo Li; Yunhe Zhao; Hui Liu; Bin Meng; Jitao Wang; Tianjun Qi; Hui Zhang; Tao Li; Peiqing Zhao; Hui Sun; Jia Xu; Haibo Song; Zhe Dong; Fengshuang An
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more
  4 in total

1.  Prognostic significance of long non-coding RNA five prime to XIST in various cancers.

Authors:  Jian Zhou; Junjie Chen; Ziyuan Chen; Gen Wu; Zhen Zhou; Tong Wu; Wanchun Wang; Yingquan Luo; Tang Liu
Journal:  BMC Cancer       Date:  2022-01-13       Impact factor: 4.430

2.  Long noncoding RNA Ftx regulates the protein expression profile in HCT116 human colon cancer cells.

Authors:  Ruzhen Jia; Lulu Song; Zhiqiang Fei; Chengyong Qin; Qi Zhao
Journal:  Proteome Sci       Date:  2022-04-30       Impact factor: 2.882

3.  Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis.

Authors:  Weiwei Chen; Yuting Li; Liliangzi Guo; Chenxing Zhang; Shaohui Tang
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

4.  Upregulation of FTX expression is associated with a poor prognosis and contributes to the progression of thyroid cancer.

Authors:  Ping Wang; Yongming Zhang; Wenping Wang; Huimin Jiang
Journal:  Oncol Lett       Date:  2021-07-18       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.